Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells

Salinas‐Vera, Yarely M.; Marchat, Laurence A.; García‐Vázquez, Raúl; Rosa, Claudia H. González-De la; Castañeda-Saucedo, Eduardo; Navarro-Tito, Napoleón; Flores, Carlos Palma; Pérez‐Plasencia, Carlos; Cruz-Colín, José L.; Carlos‐Reyes, Ángeles; López‐González, José Sullivan; Álvarez-Sánchez, María Elizbeth; López-Camarillo, César

doi:10.1016/j.canlet.2018.06.003

Cited by 35 publications

(32 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, miR-204 reduces the expression and phosphorylation of 13 proteins involved in PI3K/AKT, RAF1/MAPK, VEGF, and FAK/SRC signaling. Functional studies confirmed that miR-204 targets PI3Kα and c-SRC transducers, indicating that miR-204 exerts a fine-tuning regulation of the PI3K/AKT/FAK axis critical in VM formation and angiogenesis (49).…”

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 81%

“…miR-204 targets multiple signaling transducers involved in VM and angiogenesis in invasive triple negative MDA-MB-231 and Hs-578T breast cancer cells. Ectopic restoration of miR-204 in MDA-MB-231 cells leads to a potent inhibition of hypoxia-induced VM and reduction of number of branch points and capillary tubes (49). Finally, miR-204 reduces the expression and phosphorylation of 13 proteins involved in PI3K/AKT, RAF1/MAPK, VEGF, and FAK/SRC signaling.…”

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 96%

See 1 more Smart Citation

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

et al. 2018

View full text Add to dashboard Cite

Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored. Contents

show abstract

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 81%

Section: Angiomirs: Micrornas Modulating Angiogenesis In Human Cancersmentioning

confidence: 96%

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Twist1 as a direct and specific target of miR-490-3p can accelerate VM formation [94]. In 2018, Salinas-Vera et al showed that miR-204 regulates VM formation by targeting the PI3K/AKT/FAK signaling pathway [95]. It has been reported that miRNAs such as miR-193b, niR-125a, and let-7e suppress VM formation in breast cancer.…”

Section: Non-coding Rnas As Emerging Regulators In Tumor Vm Formationmentioning

confidence: 99%

“…Ample evidence indicates that VM is significantly associated with poor overall survival in patients, suggesting that VM potentially indicates a poor prognosis for patients with malignant tumors, such as osteosarcoma [100], gliomas [45], breast cancer [63,95], gastric cancer [16], HCC [11,68], and lung cancer [19,101]. It is known that VM is associated with tumor growth, progression, metastasis, invasion, and treatment failure.…”

Section: Clinical Significance Of Vm In Cancermentioning

confidence: 99%

Vasculogenic mimicry in carcinogenesis and clinical applications

et al. 2020

View full text Add to dashboard Cite

Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells. VM has two distinct types, namely tubular type and patterned matrix type. VM is associated with high tumor grade, tumor progression, invasion, metastasis, and poor prognosis in patients with malignant tumors. Herein, we discuss the recent studies on the role of VM in tumor progression and the diverse mechanisms and signaling pathways that regulate VM in tumors. Furthermore, we also summarize the latest findings of non-coding RNAs, such as lncRNAs and miRNAs in VM formation. In addition, we review application of molecular imaging technologies in detection of VM in malignant tumors. Increasing evidence suggests that VM is significantly associated with poor overall survival in patients with malignant tumors and could be a potential therapeutic target.

show abstract

“…This study also showed that PI3K-alpha and c-SRC are targets of miR-204. Therefore, it was proposed that miR-204 regulates critical pathways in VM, such as PI3K, MAPK, and SRC (38). Another factor associated with VM in breast cancer is osteopontin, a phosphoprotein related to tumor progression in different types of cancer.…”

Section: Factors Involved In Vm In Breast Cancermentioning

confidence: 99%

An Overview of Vasculogenic Mimicry in Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Vasculogenic mimicry (VM) is the formation of vascular channels lacking endothelial cells. These channels are lined by tumor cells with cancer stem cell features, positive for periodic acid-Schiff, and negative for CD31 staining. The term VM was introduced by Maniotis et al. (1), who reported this phenomenon in highly aggressive uveal melanomas; since then, VM has been associated with poor prognosis, tumor aggressiveness, metastasis, and drug resistance in several tumors, including breast cancer. It is proposed that VM and angiogenesis (the de novo formation of blood vessels from the established vasculature by endothelial cells, which is observed in several tumors) rely on some common mechanisms. Furthermore, it is also suggested that VM could constitute a means to circumvent anti-angiogenic treatment in cancer. Therefore, it is important to determinant the factors that dictate the onset of VM. In this review, we describe the current understanding of VM formation in breast cancer, including specific signaling pathways, and cancer stem cells. In addition, we discuss the clinical significance of VM in prognosis and new opportunities of VM as a target for breast cancer therapy.

show abstract

Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells

Cited by 35 publications

References 41 publications

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review)

Vasculogenic mimicry in carcinogenesis and clinical applications

An Overview of Vasculogenic Mimicry in Breast Cancer

Contact Info

Product

Resources

About